JPE1375 inhibits C5 - Dry AMD Intravitreal

JPE-1375 (Jerini AG, Berlin Germany) is a small molecule peptidomimetic antagonist targeting the complement pathway, a highly validated target for dry AMD.

It targets C5aR, the receptor for complement factor C5a, which is a key component involved in the activation of inflammatory cells⁽⁵⁵⁾.

JPE-1375 has shown significant efficacy in multiple preclinical models.